Category: Uncategorized

Made in EU: The long road to European health technology assessment

The joint vision for the European perspective on health policy was announced by Commission President Ursula von der Leyen in 2020 in her State of the Union address: a strong European health union that pools forces and harnesses potential. Synergy effects should be generated, for instance, by a European pharmaceutical strategy that includes guiding ideas along the entire life cycle of a drug: from research and development to early access to innovations for all EU citizens.

An important pillar of the pharmaceutical strategy is EU HTA. After decades of preparatory work, a regulation for a European benefit assessment has now been launched at the beginning of this year.

The European Health Data Space and its Opportunity for Improving Quality of Care

A key component of the European Health Union is the European Health Data Space (EHDS), which was launched by the European Commission at the beginning of May. It is one of twelve data spaces which is inteded to facilitate data exchange in the EU. The European Health Data Space is to allow efficient exchange and direct access to different health data and has the chance to improve healthcare for European patients.

(DE) 5 Jahre „Cannabis als Medizin“- Gesetz: 5 Jahre Evidenzgewinn?

(DE) Ärzte, die Cannabisarzneimittel zulasten der gesetzlichen Krankenversicherung verschreiben, waren seit März 2017 dazu verpflichtet, an einer nichtinterventionellen Begleiterhebung zur Anwendung von Cannabisarzneimitteln teilzunehmen. Die Ergebnisse der Begleiterhebung sind Grundlage für den Gemeinsamen Bundesausschuss die zukünftige Übernahme der Behandlungskosten zu regeln. Was können Patienten, Pharmaunternehmen, Ärzte und Gesetzgeber von den Ergebnissen der Begleiterhebung erwarten?

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start writing!